GlobeNewswire·Nov 10, 2026, 7:30 AM ET

Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate Update

ABUS

Arbutus Biopharma reported cash, cash equivalents, and marketable securities totaling $337.5 million as of September 30, 2026, including a $67.3 million cash dividend received from Genevant.
The company returned $230 million to shareholders via a modified Dutch Auction tender offer completed in early October 2026, purchasing 46 million shares at $5.00 per share.
Arbutus expanded international patent enforcement against Pfizer & BioNTech by filing new lawsuits in Japan & amending a Canadian lawsuit to include an additional LNP patent infringement claim.
The U.S. FDA lifted the clinical hold on the IND application for AB-101, an oral PD-L1 inhibitor, allowing further clinical development in the United States following a successful Phase 1 trial.
For the quarter ended September 30, 2026, the company reported a net income of $59.1 million ($0.30 per share), compared to a net loss of $7.7 million in the same period in 2025.
Research & development expenses decreased to $2.6 million for the quarter due to workforce reductions & lower clinical trial costs, while general & administrative expenses increased to $8.0 million driven by executive bonuses related to the Moderna settlement.
Total revenue for the quarter was $0.3 million, a decrease from $0.5 million in 2025, primarily due to lower royalty revenues from Alnylam's ONPATTRO sales.
Arbutus received $178.4 million in July 2026 as its share of the noncontingent payment from the Moderna settlement & awaits a decision on the contingent $1.3 billion appeal.
Clinical data for imdusiran (AB-729) showed eight patients achieving functional cure in Phase 2a trials, with five sustaining the cure for over two years off nucleos(t)ide analogue therapy.
As of September 30, 2026, the company had 199.3 million common shares outstanding, along with 6.4 million stock options & unvested restricted stock units.

Company: Arbutus Biopharma Corporation
Keywords: Nasdaq:ABUS, Arbutus Biopharma Corporation, Arbutus Biopharma, Q3 2026 Financial Results, Corporate Update, Q3 2026 Earnings